We recently demonstrated in vitro that a mutant HSV -TK ( mutant 75 ) expressed from an adenovirus ( AdCMV -TK75 ) radiosensitized rat RT2 glioma cells significantly better than wild type HSV -TK ( AdCMV -TK ) in combination with acyclovir ( ACV ) . To examine whether a similar improvement could also be observed in vivo, we tested these viruses in a syngeneic rat glioma tumor model ( RT2 / Fischer 344 ) . First, we demonstrate that treatment with AdCMV -TK and ACV significantly radiosensitizes implanted gliomas and roughly doubles the mean survival time to 37 days, compared to 20 days for control animals implanted with Adgaltransduced cells ( P < .02 ) . Second, it was important to first examine the effect of AdCMV -TK75 and ACV on survival without any irradiation. We found that AdCMV -TK75 appeared to sensitize gliomas more efficiently than AdCMV -TK, although this difference was not significant ( P = .19 ) . Third, and most importantly, in combined HSV -TK, ACV and irradiation experiments, we demonstrate that AdCMV -TK75 is superior over AdCMV -TK and significantly ( P < .005 ) prolonged the survival of treated animals. Our results suggest that AdCMV -TK75 is far more efficient than AdCMV -TK in radiosensitizing rat glioma when administered in combination with ACV. Cancer Gene Therapy ( 2001 ) 8, 3 ± 8
T ransduction of tumor cells with adenovirus expressing the herpes simplex virus ( HSV ) thymidine kinase ( TK )`s uicide'' gene and exposure to a prodrug, most frequently ganciclovir (GCV ), has been extensively tested in vitro and as cancer therapy of animal brain tumors in vivo and shown to produce specific and efficient killing of tumor cells. 1, 2 Phase I clinical trials using this approach are currently underway for the treatment of different types of cancers, including glioma. 3, 4 To improve further on the HSV-TK concept, we and others have demonstrated that infection of cells with an adenovirus expressing HSV-TK and exposure of these cells to one of several other HSV-TK prodrugs, including acyclovir (ACV ) and bromodeoxycytidine, can be used in combination with radiation to potentiate cellular toxicity. 5 ± 8 We recently demonstrated in vitro that a mutant HSV-TK with four amino acid alterations ( mutant 75 ) performed significantly better than wild type HSV-TK as radiosensitizer together with ACV, resulting in increased apoptosis of rat RT2 glioma cells. 8 Mutant 75 is able to use significantly lower concentrations of ACV than is wild type HSV-TK, a property that is expected to increase cell toxicity in vivo where concentrations rarely reach above the low micromolar range. 8, 9 In this report, we demonstrate that mutant HSV-TK75 performs substantially better than wild type HSV-TK as radiosensitizer of rat glioma in vivo when administered in combination with ACV. Fractionated irradiation of implanted AdCMV-TK75 ±transduced RT2 cells significantly prolonged the survival of treated animals compared to controls.
MATERIALS AND METHODS
Cell culture and growth of adenovirus RT2 cells, a rat glioma cell line derived from Fischer 344 rats that form tumors with features typical of human glioblastoma, were cultured in Dulbecco's modified Eagle's medium with 10% fetal bovine serum supplemented with penicillin /streptomycin. 8 Adenovirus expressing wild type HSV-TK ( AdCMV-TK ) , mutant HSV-TK75 (AdCMV-TK75 ), or the -galactosidase reporter (Adgal ) described previously 8 were grown in human 293 cells permissive for growth of E1 -deleted Ad -5, 10 and purified by double CsCl gradient centrifugation followed by dialysis against 13% glycerol in phosphate -buffered saline as described. 11, 12 Virus was snap -frozen in liquid nitrogen and stored at À 708C until further use. Virus titering was carried out using standard plaque assay. We routinely achieve titers in excess of 2Â10 11 pfu /mL.
Animals
All animal experiments were approved by the Medical College of Virginia Institutional Animal Care and Use Committee (IACUC) as described in protocol #9903 -2627. Female Fischer 344 rats (150 ±160 g ) were purchased from Harlan Sprague -Dawley. Animals were anesthesized and immobilized with a single intraperitoneal injection of a Ketamine ± HCl ( 50 mg / mL ) :Xylazine ( 10 mg / mL ) solution.
Intracerebral implantation of RT2 cells
Transduced RT2 cells were implanted intracerebrally using a stereotaxic frame (Stoelting, Wood Dale, IL ). Briefly, 3Â10 4 cells in 5 L infected 48 hours earlier with multiplicities of infection (MOIs ) ranging between 3 and 30 were implanted in the right parietal lobe, 3 mm to the right and 1 mm posterior to the bregma. Transduced cells were delivered with a 28-gauge infusion needle lowered to a depth of 3.5 mm to place the tip of the needle in the caudate ±putamen to avoid the ventricular space. This location avoids back flow of the infusate preventing escape along the needle track. On completion of injecting the tumor cells, the needle was withdrawn, the burr hole sealed with bone wax, and the incision closed with a wound clip. Osmotic mini -pumps (ALZET model 2ML1, ALZA Scientific Products, Palo Alto, CA, delivering 10 L/h over 7 days ) were filled with 2 mL of a 50 mg /mL solution of Zovirax 1 /acyclovir ( ACV ) from Glaxo -Wellcome, Chapel Hill, NC. The osmotic pumps were implanted subcutaneously between the scapula immediately following implantation of cells. Animals were returned to their cages and allowed to eat and drink ad libitum. Irradiations started on day 5 after implantation. Animals were anesthesized as described above for surgery, put in a shielding block, and the head exposed to 7.25 Gy delivered from a Picker Zonegard V4M60 60 Co gamma irradiator (Picker Manufacturing, Cleveland, OH) at 1 Gy /min. Radiation exposures were repeated daily for three consecutive days ( days 5 ±7 after implantation) . Animals were monitored daily for signs of abnormal behavior, i.e., circling behavior indicative of bacterial infections, early and persistent lethargy and recumbent behavior indicative of cerebral hemorrhage, at which time animals were sacrificed.
Statistical analysis
Statistical analysis was carried out by three -way variance F test analysis using the SPlus ( version 4.5) computer software. The statistical procedure of``analysis of variance'' 13 was used to detect differences between the data sets. For the pair-wise comparison between means, t test was used with adjusting the critical region of the test to accommodate the Bonnferoni correction. 14 
RESULTS
In vivo radiosensitization of RT2 glioma with AdCMV -TK and ACV
To examine whether adenovirus -expressed HSV-TK in combination with systemically administered ACV would sensitize glioma to radiation, we cerebrally implanted 3Â10 4 cells transduced in vitro with either Adgal or AdCMV-TK into syngeneic Fischer 344 rats. We determined that an MOI between 10 and 30 transduced close to 100% of the RT2 cells (data not shown) . Six animals were implanted with RT2 cells transduced with either one of the two viruses. Then, 5 days after implantation and ACV exposure ( osmotic pump ), we irradiated the brains of three animals from each set with 7.25 Gy on three consecutive days (Fig 1) . We determined that this irradiation protocol added approximately 10 days to the 20 days survival time of rats implanted with 3Â10
4 nontransduced RT2 cells (data not shown) . We found that there were significant differences in the mean survival times between the four groups (P < .001) . The mean survival time of Adgal -implanted rats exposed to ACV was $20 days ( Fig 2 ) . Fractionated irradiation (3Â7.25 Gy ) increased the survival of these animals to $28 days ( P <.025 ) . Rats implanted with AdCMV-TK ±transduced RT2 cells that were given ACV survived slightly longer ( $30 days ) than rats implanted with Adgal -transduced cells that were also irradiated. Finally, animals that received AdCMV-TK ±transduced cells and then irradiated survived for $37 days, significantly (P < .02 ) longer than animals that were not irradiated. This result clearly demonstrates that treatment with a combination of AdCMV-TK transduction and exposure to ACV radiosensitizes syngeneic rat glioma and almost doubles the survival time of AdCMV-TK ± treated animals compared to Adgal -treated control rats.
Only marginally improved effect with mutant HSV -TK75 over wild type in combination with ACV
We recently reported on the superior radiosensitizing properties of a mutant HSV-TK in combination with ACV in vitro. HSV-TK gene and selection for increased sensitivity to ACV in bacteria. 9 We demonstrated that RT2 cells infected with the adenovirus expressing the mutant HSV-TK75 ( AdCMV-TK75 ) were killed with significantly greater efficiency at low concentrations of ACV than cells infected with an adenovirus expressing wild type HSV-TK ( AdCMV-TK ), apparently by increased apoptosis. 8 To examine whether enhanced killing was also possible to achieve in vivo, we again intracerebrally implanted RT2 cells transduced in vitro with either Adgal, AdCMV-TK, or AdCMV-TK75 virus 2 days earlier. All animals received ACV from osmotic pumps, but were not given any radiation. The result of an experiment using an MOI of 30 is shown in Figure 3 . We found that there were significant differences in the mean survival between the three groups (P= .002 ). In pair-wise comparisons, animals implanted with cells transduced with AdCMV-TK lived longer ($33 days ) than animals implanted with cells transduced with Adgal ( $20 days ), which was highly significant (P < .001 ). However, rats implanted with cells transduced with the AdCMV-TK75 virus expressing mutant HSV-TK75 increased the survival to $40 days over rats implanted with AdCMV-TK ± transduced cells, but this difference was not significant ( P= .19) because of tailing of the curve. Similar, nonsignificant trends were also observed when rats were implanted with cells transduced with the lower MOI of either 3 or 10 ( data not shown ), suggesting that this marginal effect was not related to the expression level of mutant HSV-TK75 protein or the MOI.
Substantially improved radiosensitization with mutant HSV -TK75 over wild type in combination with ACV Next, to examine whether mutant HSV-TK75 improved radiosensitization of glioma compared to HSV-TK, we implanted transduced RT2 cells as before with either Adgal, AdCMV-TK, or AdCMV-TK75 virus at an MOI of 30. All animals received ACV from osmotic pumps and half the number of animals from each group were irradiated on three consecutive days, as indicated in the protocol in Figure 1 . The mean survival of animals that were not irradiated were approximately 29, 38, and 50 days for Adgal -, AdCMV-TK ± , and AdCMV-TK75 ± treated animals, respectively ( Fig 4) . Fractionated radiation increased the mean survival times for the three groups to 37, 48, and 80 days, respectively. The animals implanted with cells transduced with AdCMV-TK75 and then irradiated showed no signs of abnormal behavior and were sacrificed on day 80. We found significant ( P <.001 ) differences in the survival time of animals between the six groups. In pair-wise comparison, there was a significant ( P= .005) difference in Animals were treated the same way as described in the legend to Fig. 2 except that also AdCMV -TK75 was included in this experiment. RT2 cells were transduced at an MOI of 30. There were statistically significant differences ( P = .002 ) between the mean survival times of the three groups: o, Adgal; , AdCMV -TK; and !, AdCMV -TK75.
In pair -wise comparison, there was a statistically significant difference ( *, P < .001 ) between the mean survival times of Adgal and AdCMV -TK. However, there was no statistically significant difference ( **, P = .19 ) between the mean survival times of animal implanted with AdCMV -TK ± and AdCMV -TK75 ± transduced RT2 cells. To adjust for multiple comparison, Bonnferoni correction corresponding to P = .025 was considered.
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survival between irradiated and unirradiated animals implanted with AdCMV-TK75 ± transduced cells. However, there were no significant pair-wise differences between any other two groups in this experiment, although the trends are the same as demonstrated in the two previous experiments.
To establish the presence of tumor cells in an animal that we suspected might have succumbed to the growth of the implanted tumor cells, we sectioned the paraffin-embedded brain from an animal that had received Adgal -transduced cell and stained the sections with hematoxylin ± eosin ( Fig  5 ) . As shown, at low power, a tumor is easily distinguished as a darker stained area (Fig 5A ) , and at higher power, darker -stained nuclei of tumor cells and other infiltrating cell bodies can easily be distinguished (Fig 5B and C ) , suggesting that the cause of death of the Adgal -treated rat was a brain tumor. We were also able to identify, however, with much more difficulty, a very small lesion in the brain of a sacrificed rat implanted with cells transduced with AdCMV-TK75 that was also given ACV and fractionated irradiation ( Fig 5D ± F) . The presence of tumor cells was also evident in this animal, but much less extensively. Consequently, the most likely reason for the sustained survival of animals treated with AdCMV-TK75 virus, ACV, and fractionated irradiation was tumor growth inhibition. These results unequivocally demonstrate that mutant HSV-TK75 performs superior to wild type HSV-TK as radiosensitizer of rat glioma in vivo when administered together with ACV.
DISCUSSION
In this study, we examined whether there were any differences in therapeutic efficacy and radiosensitization in vivo between adenoviruses expressing different forms of the HSV-TK``suicide gene'' when administered together with ACV. Acyclovir is the drug of choice for the treatment of herpes -associated encephalitis in children, 15 and we recently demonstrated that irradiation potentiates cell killing with HSV-TK /ACV treatment in vitro. 8 We were not interested in optimizing in vivo gene delivery or refining brain surgery of rats, but in examining whether HSV-TK75 performed with AdCMV -TK75 ( + IR ) were sacrificed on day 80 ( * ) . In pair -wise comparison, there was a statistically significant difference ( **, P = .005 ) between the mean survival times of animals implanted with cells transduced with AdCMV -TK75 that did not receive any radiation, AdCMV -TK75 ( À IR ) , and animals that did, AdCMV -TK75 ( + IR ) . However, there was no statistically significant difference ( P = .07 ) between AdCMV -TK ( À IR ) and AdCMV -TK ( + IR ) . There was also no statistically significant difference ( P = .20 ) between Adgal ( À IR ) and Adgal ( + IR ) . There was also no statistically significant difference ( P = .03 vs P = .0125 and familywise error rate = .05 ) between AdCMV -TK ( À IR ) and AdCMV -TK75 ( À IR ) . To adjust for multiple comparison, Bonnferoni correction corresponding to P = .0125 was considered.
Cancer Gene Therapy, Vol 8, No 1, 2001 better than wild type HSV-TK as radiosensitizer of malignant glioma together with ACV. Therefore, we chose to transduce the RT2 glioma cells in vitro before intracerebrally implanting the cells to focus on the radiosensitizing effects of the HSV-TK /ACV treatment and to show clear proof of principle of our approach. Transduction frequencies of RT2 cells in vitro can easily reach 100%, a level that might not be attained by direct infusion of adenovirus into an existing brain tumor.
Even with relatively few animals used in this study, we demonstrate significant differences in radiosensitization. Animals implanted with RT2 cells transduced with the adenovirus expressing wild type HSV-TK and exposed to ACV survived approximately twice as long as animals implanted with Adgal -transduced cells. Without irradiation, mutant HSV-TK75 seemed to perform better than HSV-TK in each of three experiments using a range of different MOIs ( 3± 30 ), but the results were not significant because of tailing of the survival curve. However, because this trend was quite reproducible, it is very likely that HSV-TK75 performs significantly better than wild type HSV-TK when tested in larger studies. The most important and significant finding in the present study is that animals implanted with cells transduced with a virus expressing mutant HSV-TK75 followed by systemic administration of ACV and fractionated irradiation resulted in prolonged survival of animals. This dramatic response did not occur with any other combination of virus, drug, or irradiation treatment. Because animals that received cells transduced with virus expressing mutant HSV-TK75 and ACV but no irradiation lived approximately as long as animals that received wild type HSV-TK virus, ACV, and irradiation, this result strongly suggests that radiation and HSV-TK75 specifically synergize to significantly improve the survival of treated rats.
In agreement with our in vitro results demonstrating that AdCMV-TK75 performed significantly better than AdCMV-TK as radiosensitizer in combination with ACV, 8 we observed a significantly improved radiosensitizing effect of AdCMV-TK75 also in vivo. However, the most striking observation made from our in vivo study is the pronounced and quantitative effect irradiation had on the HSV-TK75 / ACV ± treated rats compared to animals transduced with virus expressing wild type HSV-TK that was not apparent in vitro. In other words, radiosensitization with HSV-TK75 and ACV works better than expected based on our in vitro results. It is possible that expression of HSV-TK75, by itself, generates some unknown effect on the tumor cells to increase radiosensitivity, e.g., by causing an imbalance in cellular nucleoside pools, although at this point we have no experimental evidence for this happening either in vitro or in vivo. Future experimentation will reveal whether this notion is true or not and whether a similar superior effect of AdCMV-TK75 is also observed in human xenografts grown in nude mice.
One earlier study examined the radiosensitizing effects of HSV-TK and ACV on malignant gliomas in rats. 6 However, in that study, cells were stably transduced with a retrovirus expressing HSV-TK rather than transiently expressed from an adenovirus. In immune-competent rats, which is what we used in the present study, adenovirus infection of tumor cells elicits a strong immune response that may help suppress tumor growth and improve therapy. 16 Furthermore, recent studies have demonstrated increased cell killing in vitro and in vivo using a threepronged scheme involving radiation and a cytosine deaminase ± HSV-TK fusion protein in combination with 5-fluorocytosine and GCV treatments that showed a significant improvement in cell killing over existing, single,`s uicide'' gene approaches. 17, 18 Other studies have also shown improved in vivo efficacy with HSV-TK ± based therapy using oncolytic adenovirus. 18, 19 Increasing the toxicity of viral``suicide'' vectors probably also increases the chances for toxic side effects to normal tissues. For most tumor targets, GCV may prove a better choice than ACV as prodrug because of a lower K i . 20, 21 Under certain circumstances, e.g., when the target is the brain, there are good reasons for choosing ACV over GCV. Acyclovir is the drug of choice for treating patients with herpes -associated encephalitis, 15 may not be as toxic as GCV, and appears to cross the blood ±brain barrier more efficiently than GCV. 22 Our results using the HSV-TK75 adenovirus suggest that radiation can serve as a``trigger'' for very efficient cell killing in vivo in combination with ACV, a treatment which without irradiation may be less toxic than the conventional HSV-TK / GCV combination. Nonspecific toxicity is thus expected to be lower. Another, perhaps even more serious limitation and major technical obstacle yet to be overcome is how to deliver adenovirus vectors efficiently into tumors and to avoid unintentional expression of thè`s uicide'' gene in surrounding normal tissues. This problem may be particularly serious if it occurs in the brain. 23 In summary, the results from our study strongly suggest that treatment with AdCMV-TK75 adenovirus expressing mutant HSV-TK75 would significantly improve HSV-TK ±based radiosensitization of malignant glioma in combination with ACV.
